In The News

Drug Industry May Face Less Scrutiny Under Trump

Bloomberg BNA, Health Care Daily Report

14 Nov 2016

David Manspeizer, a partner in Morrison & Foerster’s IP Litigation Group, was quoted regarding the 2016 election results and how they affect the drug industry in the article, “Drug Industry May Face Less Scrutiny Under Trump,” published by Bloomberg BNA’s Health Care Daily Report on November 14, 2016.

“Industry will be concerned about Trump reopening trade agreements and the possibility of renegotiating those agreements,” Mr. Manspeizer said.

There’s also the possibility that the issue of whether cheaper drugs can be legally imported into the U.S. could resurface, he said.

Trump has made “vague statements” on importation and the reimportation of drugs from Canada, he said. Trump has also made statements about opening up Medicare Part D, which covers prescription drugs, to price negotiation, Mr. Manspeizer said.

The lack of “meat on the bones” on any of Trump’s statements makes it difficult to predict what, if anything, could move forward in these areas, he said.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.